EXACT Sciences Corporation - Asset Resilience Ratio
EXACT Sciences Corporation (EXAS) has an Asset Resilience Ratio of 0.15% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check EXACT Sciences Corporation strategic capital allocation to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2002–2025)
This chart shows how EXACT Sciences Corporation's Asset Resilience Ratio has changed over time. See how leveraged is EXACT Sciences Corporation's balance sheet to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down EXACT Sciences Corporation's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see EXAS market cap.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $8.71 Million | 0.15% |
| Total Liquid Assets | $8.71 Million | 0.15% |
Asset Resilience Insights
- Limited Liquidity: EXACT Sciences Corporation maintains only 0.15% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
EXACT Sciences Corporation Industry Peers by Asset Resilience Ratio
Compare EXACT Sciences Corporation's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Fleury S.A.
SA:FLRY3 |
Diagnostics & Research | 16.06% |
|
Wuhan Thalys Med Tech Co Ltd
SHG:603716 |
Diagnostics & Research | 0.12% |
|
Spectral Med Inc
TO:EDT |
Diagnostics & Research | 11.67% |
|
Bcal Diagnostics Ltd
AU:BDX |
Diagnostics & Research | 0.00% |
|
Genetic Signatures Ltd
AU:GSS |
Diagnostics & Research | 60.91% |
|
Sonic Healthcare Ltd
AU:SHL |
Diagnostics & Research | 0.13% |
|
Australian Clinical Labs Ltd
AU:ACL |
Diagnostics & Research | 4.11% |
|
Monash Ivf Group Ltd
AU:MVF |
Diagnostics & Research | 1.60% |
Annual Asset Resilience Ratio for EXACT Sciences Corporation (2002–2025)
The table below shows the annual Asset Resilience Ratio data for EXACT Sciences Corporation.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.15% | $8.71 Million | $5.86 Billion | -7.23pp |
| 2024-12-31 | 7.37% | $437.14 Million | $5.93 Billion | +4.71pp |
| 2023-12-31 | 2.66% | $172.27 Million | $6.47 Billion | -3.59pp |
| 2022-12-31 | 6.26% | $389.56 Million | $6.23 Billion | -4.44pp |
| 2021-12-31 | 10.70% | $715.00 Million | $6.68 Billion | +3.62pp |
| 2020-12-31 | 7.08% | $348.70 Million | $4.93 Billion | +2.90pp |
| 2019-12-31 | 4.18% | $146.40 Million | $3.51 Billion | -59.06pp |
| 2018-12-31 | 63.24% | $963.75 Million | $1.52 Billion | +5.23pp |
| 2017-12-31 | 58.01% | $347.22 Million | $598.56 Million | -11.53pp |
| 2016-12-31 | 69.54% | $262.18 Million | $377.04 Million | -3.41pp |
| 2015-12-31 | 72.95% | $265.74 Million | $364.30 Million | +0.87pp |
| 2014-12-31 | 72.08% | $224.62 Million | $311.62 Million | -10.04pp |
| 2013-12-31 | 82.12% | $120.41 Million | $146.63 Million | -2.41pp |
| 2012-12-31 | 84.53% | $94.78 Million | $112.12 Million | +25.14pp |
| 2011-12-31 | 59.39% | $57.58 Million | $96.95 Million | +42.12pp |
| 2010-12-31 | 17.26% | $16.66 Million | $96.52 Million | +7.94pp |
| 2009-12-31 | 9.33% | $2.40 Million | $25.77 Million | -46.18pp |
| 2007-12-31 | 55.51% | $8.10 Million | $14.60 Million | -12.55pp |
| 2006-12-31 | 68.06% | $16.24 Million | $23.87 Million | +12.27pp |
| 2005-12-31 | 55.79% | $21.11 Million | $37.84 Million | -10.49pp |
| 2004-12-31 | 66.28% | $37.19 Million | $56.11 Million | +27.04pp |
| 2003-12-31 | 39.23% | $13.61 Million | $34.68 Million | -13.49pp |
| 2002-12-31 | 52.72% | $26.41 Million | $50.09 Million | -- |
About EXACT Sciences Corporation
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. It offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer; Cologuard Plus Tests; Cancerguard Test; and Genetic Testing. The company also provides Oncotype DX Breast Recurrence S… Read more